Study finds limited drugs for neglected conditions in R&D pipeline

Research and development of drugs for neglected conditions has been slow, with only 37 of the 850 vaccines and medicines approved in the past 10 years intended for such diseases, according to a study in The Lancet Global Health. This sluggish growth can be attributed in part to a lack of financial rewards to spur drug and biotech firms to allocate funds for the development of therapies for conditions such as malaria and Chagas disease, the study notes.

View Full Article in:

New York Times (tiered subscription model), The · Voice of America

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA